What is Rxsight?
Founded in 1997 and headquartered in California, RxSight operates at the intersection of advanced optics and surgical precision. The company specializes in the development of the first and only adjustable intraocular lens that allows doctors to optimize a patient's vision after cataract surgery. By utilizing a proprietary light-delivery device, RxSight enables clinicians to customize the refractive power of the lens in an office setting, effectively addressing the limitations of traditional, non-adjustable implants. This technology represents a paradigm shift in ophthalmology, moving from a one-size-fits-all approach to a personalized, patient-centric model that significantly improves visual acuity and satisfaction.
How much funding has Rxsight raised?
Rxsight has raised a total of $317.8M across 7 funding rounds:
Private Equity
$8.5M
Private Equity
$12.7M
Private Equity
$52M
Debt
$17M
Private Equity
$50M
Debt
$60M
Share Placement
$117.6M
Private Equity (2009): $8.5M, investors not publicly disclosed
Private Equity (2011): $12.7M, investors not publicly disclosed
Private Equity (2015): $52M supported by RA Capital Management, Longitude Capital, H.I.G. BioVentures, and Balance Point Capital
Debt (2015): $17M, investors not publicly disclosed
Private Equity (2017): $50M, investors not publicly disclosed
Debt (2020): $60M with participation from Oxford Finance
Share Placement (2021): $117.6M, investors not publicly disclosed
Key Investors in Rxsight
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
H.I.G. BioVentures
H.I.G. Capital is a global alternative investment firm providing debt and equity capital to small and middle-market companies, with a dedicated focus on healthcare and life sciences.
Oxford Finance
Oxford Finance is a specialty finance firm that offers flexible financial solutions and debt capital to healthcare and life sciences companies worldwide.
What's next for Rxsight?
With the recent influx of capital, RxSight is poised to accelerate its market penetration and invest in the next generation of refractive solutions. The strategic focus will likely center on expanding the clinical adoption of its light-adjustable lens platform, enhancing physician training programs, and potentially exploring new indications for its core technology. As the company transitions into a more mature phase of its lifecycle, the emphasis will shift toward operational efficiency and long-term value creation for stakeholders. By maintaining its focus on evidence-based innovation and clinical outcomes, RxSight is set to remain a dominant force in the global ophthalmic market, setting new standards for post-surgical vision correction.
See full Rxsight company page
